DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer

被引:6
作者
Wang, Jieyu [1 ,2 ]
Li, Jun [1 ]
Chen, Ruifang [1 ]
Yue, Huiran [1 ]
Li, Wenzhi [1 ,2 ]
Wu, Beibei [1 ]
Bai, Yang [1 ]
Zhu, Guohua [1 ,2 ]
Lu, Xin [1 ,2 ]
机构
[1] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, 128 Shenyang Rd, Shanghai 200090, Peoples R China
[2] Fudan Univ, Shanghai Key Lab Female Reprod Endocrine Related, Shanghai, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
Ovarian cancer; High-grade serous ovarian cancer; DNA profiling; Methylation subtypes; Prognosis; EXPRESSION; GENE; CLASSIFICATION; ASSOCIATION; RESISTANCE; SIGNATURES; METHYLOME; DIAGNOSIS; PATTERNS;
D O I
10.1186/s13148-021-01178-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade serous ovarian cancer (HGSOC) is the most common type of epigenetically heterogeneous ovarian cancer. Methylation typing has previously been used in many tumour types but not in HGSOC. Methylation typing in HGSOC may promote the development of personalized care. The present study used DNA methylation data from The Cancer Genome Atlas database and identified four unique methylation subtypes of HGSOC. With the poorest prognosis and high frequency of residual tumours, cluster 4 featured hypermethylation of a panel of genes, which indicates that demethylation agents may be tested in this group and that neoadjuvant chemotherapy may be used to reduce the possibility of residual lesions. Cluster 1 and cluster 2 were significantly associated with metastasis genes and metabolic disorders, respectively. Two feature CpG sites, cg24673765 and cg25574024, were obtained through Cox proportional hazards model analysis of the CpG sites. Based on the methylation level of the two CpG sites, the samples were classified into high- and low-risk groups to identify the prognostic information. Similar results were obtained in the validation set. Taken together, these results explain the epigenetic heterogeneity of HGSOC and provide guidance to clinicians for the prognosis of HGSOC based on DNA methylation sites.
引用
收藏
页数:12
相关论文
共 50 条
[31]   Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer [J].
Li-yuan Feng ;
Bing-bing Yan ;
Yong-zhi Huang ;
Li Li .
Clinical Epigenetics, 2021, 13
[32]   A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids [J].
Senkowski, Wojciech ;
Gall-Mas, Laura ;
Falco, Matias Marin ;
Li, Yilin ;
Lavikka, Kari ;
Kriegbaum, Mette C. ;
Oikkonen, Jaana ;
Bulanova, Daria ;
Pietras, Elin J. ;
Vossgrone, Karolin ;
Chen, Yan-Jun ;
Erkan, Erdogan Pekcan ;
Dai, Jun ;
Lundgren, Anastasia ;
Hog, Mia Kristine Gronning ;
Larsen, Ida Marie ;
Lamminen, Tarja ;
Kaipio, Katja ;
Huvila, Jutta ;
Virtanen, Anni ;
Engelholm, Lars ;
Christiansen, Pernille ;
Santoni-Rugiu, Eric ;
Huhtinen, Kaisa ;
Carpen, Olli ;
Hynninen, Johanna ;
Hautaniemi, Sampsa ;
Vaharautio, Anna ;
Wennerberg, Krister .
DEVELOPMENTAL CELL, 2023, 58 (12) :1106-+
[33]   Cell Origins of High-Grade Serous Ovarian Cancer [J].
Kim, Jaeyeon ;
Park, Eun Young ;
Kim, Olga ;
Schilder, Jeanne M. ;
Coffey, Donna M. ;
Cho, Chi-Heum ;
Bast, Robert C., Jr. .
CANCERS, 2018, 10 (11)
[34]   High-grade serous ovarian cancer: the clone wars [J].
Aleksander Salomon-Perzyński ;
Magdalena Salomon-Perzyńska ;
Bogdan Michalski ;
Violetta Skrzypulec-Plinta .
Archives of Gynecology and Obstetrics, 2017, 295 :569-576
[35]   Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival [J].
Williams, Emma ;
Martin, Stewart ;
Moss, Robert ;
Durrant, Lindy ;
Deen, Suha .
VIRCHOWS ARCHIV, 2012, 461 (01) :33-39
[36]   Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer [J].
Tserpeli, Victoria ;
Stergiopoulou, Dimitra ;
Londra, Dora ;
Giannopoulou, Lydia ;
Buderath, Paul ;
Balgkouranidou, Ioanna ;
Xenidis, Nikolaos ;
Grech, Christina ;
Obermayr, Eva ;
Zeillinger, Robert ;
Pavlakis, Kitty ;
Rampias, Theodoros ;
Kakolyris, Stylianos ;
Kasimir-Bauer, Sabine ;
Lianidou, Evi S. .
CANCERS, 2021, 14 (01)
[37]   Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors [J].
Oliveira, Douglas V. N. P. ;
Biskup, Edyta ;
O'Rourke, Colm J. ;
Hentze, Julie L. ;
Andersen, Jesper B. ;
Hogdall, Claus ;
Hogdall, Estrid V. .
MOLECULAR DIAGNOSIS & THERAPY, 2024, :821-834
[38]   A DNA methylation-based definition of biologically distinct breast cancer subtypes [J].
Stefansson, Olafur A. ;
Moran, Sebastian ;
Gomez, Antonio ;
Sayols, Sergi ;
Arribas-Jorba, Carlos ;
Sandoval, Juan ;
Hilrnarsdottir, Holrnfridur ;
Olafsdottir, Elinborg ;
Tryggvadottir, Laufey ;
Jonasson, Jon G. ;
Eyfjord, Jorunn ;
Esteller, Manel .
MOLECULAR ONCOLOGY, 2015, 9 (03) :555-568
[39]   DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers [J].
Gull, Nicole ;
Jones, Michelle R. ;
Peng, Pei-Chen ;
Coetzee, Simon G. ;
Silva, Tiago C. ;
Plummer, Jasmine T. ;
Reyes, Alberto Luiz P. ;
Davis, Brian D. ;
Chen, Stephanie S. ;
Lawrenson, Kate ;
Lester, Jenny ;
Walsh, Christine ;
Rimel, Bobbie J. ;
Li, Andrew J. ;
Cass, Ilana ;
Berg, Yonatan ;
Govindavari, John-Paul B. ;
Rutgers, Joanna K. L. ;
Berman, Benjamin P. ;
Karlan, Beth Y. ;
Gayther, Simon A. .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
[40]   Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma [J].
Kim, Se Ik ;
Lee, Hyung-Chul ;
Yoon, Hyun-Kyu ;
Kim, Hee Seung ;
Chung, Hyun Hoon ;
Kim, Jae-Weon ;
Park, Noh Hyun ;
Song, Yong-Sang ;
Lee, Maria .
BMC CANCER, 2022, 22 (01)